Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Historical Holders from Q4 2015 to Q3 2025

Symbol
KURA on Nasdaq
CUSIP
50127T109
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
87M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
84M
Holdings value
$743M
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
199
Number of buys
120
Number of sells
-73
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 9.99% +31.1% $76.8M $24.5M 8.68M +46.8% BVF PARTNERS L P/IL Sep 30, 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +38.6% $49.2M $15.4M 7.56M +45.5% SUVRETTA CAPITAL MANAGEMENT, LLC Mar 31, 2025
BlackRock, Inc. 7.8% -24% $41.2M -$10.4M 6.33M -20.2% BlackRock, Inc. Mar 31, 2025
ARMISTICE CAPITAL, LLC 5.37% -27.8% $41.3M -$16.8M 4.67M -28.9% Armistice Capital, LLC Sep 30, 2025
EcoR1 Capital, LLC 4.8% $23.5M 4.2M EcoR1 Capital, LLC Jun 30, 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% $26.1M 4M RA Capital Management, L.P. Mar 31, 2025

Institutional Holders of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 84M $743M +$26.6M $8.85 199
2025 Q2 82.2M $474M +$3.89M $5.77 180
2025 Q1 80.5M $531M -$1.74M $6.60 183
2024 Q4 78.8M $686M -$218M $8.71 184
2024 Q3 82.4M $1.61B +$3.96M $19.54 178
2024 Q2 80.5M $1.66B -$4.56M $20.59 173
2024 Q1 80.7M $1.72B +$46.7M $21.33 162
2023 Q4 77.1M $1.11B +$24.4M $14.38 137
2023 Q3 75.3M $687M -$2.21M $9.12 130
2023 Q2 75.1M $795M +$20.1M $10.58 148
2023 Q1 72.4M $885M +$27.4M $12.23 140
2022 Q4 70.1M $870M -$25.4M $12.41 137
2022 Q3 71.5M $977M -$9.89M $13.66 143
2022 Q2 68.6M $1.26B +$54.2M $18.33 142
2022 Q1 65.8M $1.06B +$39.6M $16.08 141
2021 Q4 64.1M $897M -$108M $14.00 144
2021 Q3 66.7M $1.25B -$22.7M $18.73 151
2021 Q2 67.6M $1.41B -$33.8M $20.85 163
2021 Q1 68.5M $1.94B +$107M $28.27 161
2020 Q4 65M $2.12B +$356M $32.66 194
2020 Q3 53.7M $1.65B +$52.4M $30.64 159
2020 Q2 52.3M $853M +$213M $16.30 128
2020 Q1 39.6M $393M +$5.05M $9.95 112
2019 Q4 38.8M $534M -$19.4M $13.75 125
2019 Q3 40.1M $609M +$18.5M $15.17 113
2019 Q2 38.6M $761M +$132M $19.69 120
2019 Q1 32M $531M -$3.58M $16.59 100
2018 Q4 32.4M $455M -$2.76M $14.04 94
2018 Q3 30.2M $529M +$7.59M $17.50 112
2018 Q2 29.7M $541M +$113M $18.20 108
2018 Q1 23.6M $442M +$77.4M $18.75 97
2017 Q4 19.5M $299M +$581K $15.30 73
2017 Q3 19.4M $290M +$129M $14.95 64
2017 Q2 10.8M $101M +$4.77M $9.30 42
2017 Q1 10.3M $90.7M +$4.18M $8.80 34
2016 Q4 9.88M $58.2M +$736K $5.90 29
2016 Q3 9.75M $60.9M +$2.85M $6.25 25
2016 Q2 9.32M $25.2M -$3.68M $2.71 25
2016 Q1 10.2M $40.7M -$956K $4.05 20
2015 Q4 10.2M $86.1M +$80.3M $8.40 14